Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUC398 in Symptomatic Knee Osteoarthritis
2023-509274-28-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, triple-blind trial in knee osteoarthritis (OA) comparing QUC398 with Placebo (2 arms). Primary endpoint: Change from baseline in KOOS Pain subscale at Week 12. Started Apr 2024; status: completed.
02
Drugs
QUC398
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2023-509274-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509274-28-00.